The Neurology Department at Massachusetts General Hospital is currently recruiting participants to take part in a multi-site NIH-sponsored study investigating the possible neuroprotective properties of Pioglitazone (ACTOS (R)) in individuals with early stage Parkinson's disease (PD). The purpose of this study is to determine whether Pioglitazone, a drug currently approved by the FDA to treat type II diabetes, may be useful in interrupting the progression of PD. Potential participants must be able to travel to MGH for six onsite visits over the course of approximately twelve months. Additionally, participants must currently be taking 1mg of rasagiline per day or 10mg of selegiline per day.
To learn more about enrolling in this study, please contact:
Sarah Pearl Aronow-Werner at (617) 643-7288
or
Anne-Marie Wills, MD, MPH at (617) 726-5532